Latest Content

Delivering Answers to Pressing Questions About Cancer

December 16th 2024, 8:00pm

By Mike Hennessy Jr.

Article

At CURE, we remain steadfastly dedicated to providing our readers with answers about cancer research.

My Dog and Thoughts of Gratitude After Cancer

December 16th 2024, 6:00pm

By Mary Sansone

Article

During this holiday season, I wanted to take a moment and reflect on how my dog Payton stayed by my side during acute myeloid leukemia.

Tecartus After Outpatient Lymphodepletion Safe, Effective in B-ALL and MCL

December 16th 2024, 4:00pm

By Chris Ryan

Article

Outpatient lymphodepletion followed by Tecartus was found to be safe and effective in treating B-cell acute lymphoblastic leukemia and mantle cell lymphoma.

Camrelizumab Plus Chemo May Be New Presurgical Option in Breast Cancer Subset

December 16th 2024, 2:00pm

By Kristi Rosa

Article

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.

An Extraordinary Healer Inside and Out

December 15th 2024, 4:00pm

By Colleen Bruen, RN, BSN, BMTCN

Article

Oncology nurse Denise always makes it a point to focus on the “big picture” for all of her patients with cancer.

CAN-2409 Elicits Promising Responses in Localized Prostate Cancer

December 14th 2024, 7:00pm

By Alex Biese

Article

CAN-2409 resulted in disease-free survival improvements for patients with high-risk, localized prostate cancer.

SOXRC Regimen Improves Responses Versus Chemo Alone in Advanced Gastric Cancers

December 14th 2024, 3:00pm

By Alex Biese

Article

Patients with locally advanced gastric cancers saw complete response rates of 18.3% from camrelizumab and rivoceranib plus chemotherapy.

FDA Approves Unloxcyt for Locally Advanced, Metastatic Skin Cancer Subset

December 13th 2024, 11:52pm

By Ashley Chan

Article

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell carcinoma.

Tecentriq Regimen Misses End Goal in Triple-Negative Breast Cancer

December 13th 2024, 9:37pm

By Jason Broderick

Article

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.

Cancer Taught Me to Make the Best of Everything

December 13th 2024, 6:00pm

By Jane Biehl Ph.D.

Article

As a survivor of MDS, I’ve learned to make the best of every day and to be thankful for life. Sometimes this means avoiding others who are less grateful.

‘Golden Bachelor’ Reveals Cancer Diagnosis, Ryne Sandberg’s Cancer Has Returned and More

December 13th 2024, 4:00pm

By Alex Biese

Article

From Gerry Turner announcing he has cancer to the return of a Chicago Cubs legend’s disease, here’s what’s happening in the cancer space this week.

HER3-DXd With or Without Femara Effective for Some With High-Risk Breast Cancer

December 13th 2024, 3:00pm

By Kristi Rosa

Article

Patients with high-risk, HR-positive, HER2-negative breast cancer treated with HER3-DXd with or without Femara (letrozole) experienced fewer side effects than with chemotherapy.

Understanding Genetics May Predict Treatment Response in Triple-Negative Breast Cancer

December 13th 2024, 2:00pm

By Jordyn Sava

Article

Several biomarkers may predict improved treatment responses and outcomes in patients with triple-negative breast cancer.

Postoperative Radiation Offers Higher Quality of Life, Fewer Side Effects in Some with Breast Cancer

December 12th 2024, 10:00pm

By Tim Cortese

Article

Radiation therapy resulted in improved quality of life and fewer side effects for older patients with stage 1 luminal-like breast cancer than endocrine therapy.

CDK4/6 Inhibitor Combos Miss Survival Goal in Metastatic Breast Cancer Subset

December 12th 2024, 8:43pm

By Morgan Bayer

Article

No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations during initial treatment for HR-positive, HER2-negative metastatic breast cancer.